Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novo Nordisk Nabs Diabetes Start-ups …
by Michael McCoy
September 7, 2015
| A version of this story appeared in
Volume 93, Issue 35
Novo Nordisk has agreed to acquire Calibrium and MB2, two diabetes-related start-ups cofounded by Richard DiMarchi, a chemistry professor at Indiana University. Founded in 2013, Calibrium is developing novel peptides for the treatment of diabetes and related metabolic diseases. MB2, founded a year later, is advancing a pipeline of mixed agonist drugs for diabetes and obesity. Earlier in his career, DiMarchi was an Eli Lilly & Co. R&D executive involved in discovering the diabetes drugs Humulin and Humalog.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter